Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2007
12/21/2007CA2655355A1 Use of rpn2 gene expression inhibitor
12/21/2007CA2654791A1 A method of reducing amyloid-beta peptide levels using a bisdioxopiperazine
12/21/2007CA2654021A1 Use of adipose-tissue cell fractions for post-irradiation tissue regeneration
12/20/2007US20070293683 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293673 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293672 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293579 Use of carp inhibitors for the treatment of heart diseases
12/20/2007US20070293572 Anti-Fatigue Composition
12/20/2007US20070293564 Dimeric compounds and their use as anti-viral agents
12/20/2007US20070293555 4-methoxy-benzoic acid 1-imidazol-1-yl methyl-2-(4-fluorophenoxy)-ethyl ester; N-[(1-imidazol-1-yl methyl)-2-phenoxy-ethyl]-4-iodo-benzamide; cancer, inflammation, septic shock, infertility, preterm labor, pain, or an ischemia
12/20/2007US20070293536 Salts and polymorphs of a potent antidiabetic compound
12/20/2007US20070293524 Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade
12/20/2007US20070293523 inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents
12/20/2007US20070293522 2,4-pyrimidinediamine compounds and their uses
12/20/2007US20070293521 inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents
12/20/2007US20070293520 2,4-pyrimidinediamine compounds and their uses
12/20/2007US20070293519 Analogs of thalidomide as potential angiogenesis inhibitors
12/20/2007US20070293512 2-[4-(4-Chlorophenylthio)-3-nitrophenyl]-4-mercaptothiazolo[5,4-d]pyrimidine; hyperuricemia; gout
12/20/2007US20070293504 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293503 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
12/20/2007US20070293500 Quinazoline derivatives as medicaments
12/20/2007US20070293496 Nitrogen containing heterocyclic compounds and medicines containing the same
12/20/2007US20070293477 Novel Compounds
12/20/2007US20070293453 Combinatorial Methods For Inducing Cancer Cell Death
12/20/2007US20070293452 Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
12/20/2007US20070293451 Regulation ao ApoB by Hsp110 proteins and related compositions and methods
12/20/2007US20070293441 High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
12/20/2007US20070293438 Antibody specifically binding to sulfonylated protein protein and method for producing the same
12/20/2007US20070293431 Method for improving neurotransmission failure using a novel agent
12/20/2007US20070293425 Mutein of a Bone Morphogenetic Protein and Use Thereof
12/20/2007US20070293423 Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
12/20/2007US20070293421 Erythropoietin for Treatment of Multi-Organ Failure
12/20/2007US20070292933 Inhibitors of serine proteases, particular HCV NS3-NS4A protease
12/20/2007US20070292885 Human cdnas and proteins and uses thereof
12/20/2007US20070292539 Anti-inflammatory cranberry flavonol extract preparations
12/20/2007US20070292526 Combining a reverse micelle solution with silica-, alumina-, titanium dioxide-, iron oxide-, and/or zirconium dioxide-based gel precursor solution containing catalyst, a condensation agent (H2O), and polar solvent, one of which contains an active material, to generate droplets containing active material
12/20/2007US20070292525 Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
12/20/2007US20070292506 Sustained release formulations
12/20/2007US20070292478 Medical Implant Provided with Inhibitors of Atp Synthesis
12/20/2007US20070292453 RNA virus vaccines and methods
12/20/2007US20070292448 Preloaded dendritic cell vaccines for treating cancer
12/20/2007US20070292440 CD154 blockade therapy for pancreatic islet tissue transplantation
12/20/2007US20070292431 4-1Bb Receptors are Expressed on Regulatory T-Cells
12/20/2007US20070292430 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
12/20/2007US20070292427 Substantially pure steroidogenesis inducing peptide and uses thereof
12/20/2007US20070292426 Methods and compositions based on Shiga toxin type 1 protein
12/20/2007US20070292424 Novel human eosinophil-derived basic protein
12/20/2007US20070292423 Method of Defining the Differentiation Grade of Tumor
12/20/2007US20070292419 Treatment with anti-erbb2 antibodies
12/20/2007US20070292418 Compositions and methods for immunotherapy
12/20/2007US20070292415 Compositions and methods for the therapy and diagnosis of breast cancer
12/20/2007US20070292412 Novel genes and markers in type 2 diabetes and obesity
12/20/2007US20070292411 Antibodies That Immunospecifically Bind to TRAIL Receptors
12/20/2007US20070292399 Co-culture of placental stem cells and stem cells from a second source
12/20/2007US20070292396 Combination therapy with oncolytic adenovirus
12/20/2007US20070292369 Method for preventing and reducing tartar buildup
12/20/2007US20070292368 Oral care composition
12/20/2007US20070292349 Itpks as Modifiers of the Igfr Pathway and Methods of Use
12/20/2007US20070292348 Treating Wnt signaling-related diseases, for detecting mammary basal-like cells, for diagnosing basal-like breast cancer, and for inhibiting proliferation of a tumor expressing LRP6
12/20/2007DE19943708B4 Neue C13-substituierte Estra-1,3,5(10)-trien-3-yl-sulfamate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen New C13-substituted estra-1,3,5 (10) -triene-3-yl-sulfamate, to their preparation and to pharmaceutical compositions containing these compounds, method
12/19/2007EP1867721A1 Angiostatin fragments and aggregate angiostatin and methods of use
12/19/2007EP1867718A2 Therapeutically useful synthetic oligonucleotides
12/19/2007EP1867656A1 Compound having cyclic structure and use thereof
12/19/2007EP1867642A1 Agent for prevention or treatment of nocturnal behavioral disorder associated with dementia
12/19/2007EP1867641A1 Preventive or remedy for depression or anxiety neurosis
12/19/2007EP1867640A1 Agent for treatment of solid tumor
12/19/2007EP1867639A1 Urea derivative, medicinal composition containing the same, and medicinal use of these
12/19/2007EP1867633A1 Polyamine analogues as therapeutic and diagnostic agents
12/19/2007EP1867343A2 Novel compounds
12/19/2007EP1867342A1 Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
12/19/2007EP1867341A1 Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease
12/19/2007EP1867339A1 Anti-viral agent
12/19/2007EP1867337A1 Medicinal composition for treating/preventing motor organ disease
12/19/2007EP1867333A1 Pharmaceutical composition comprising condensed indole compound
12/19/2007EP1867332A1 Pharmaceutical composition and method using antifungal agent in combination
12/19/2007EP1867329A2 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds
12/19/2007EP1865964A1 Topical formulations for use in the treatment or prevention of dermatological conditions
12/19/2007EP1865949A2 Modulators of atp-binding cassette transporters
12/19/2007EP1865779A2 Compositions and methods for ameliorating cachexia
12/19/2007EP1497261B1 Phenethanolamine derivatives
12/19/2007EP1470122B1 Rho-kinase inhibitors
12/19/2007EP1453806B1 Aminotetralin derivatives as muscarinic receptor antagonist
12/19/2007EP1422224B1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
12/19/2007EP1406872B1 Dipeptidyl peptidase inhibitors for the treatment of diabetes
12/19/2007EP1370521B1 Formanilide derivatives as beta2-adrenoreceptor agonists
12/19/2007EP1353694B1 Combinations of ezetimibe with aspirine for treating vascular conditions
12/19/2007EP1347967B1 Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
12/19/2007EP1326856B1 Pyridine derivatives with ikb-kinase (ikk-beta) inhibiting activity
12/19/2007EP1303599B1 Methylated nucleotide regulation of upa gene expression
12/19/2007EP1292596B1 1,3,8-triaza-spiro¬4,5 decan-4-one derivatives as neurokinin receptor antagonists
12/19/2007EP1284729A4 A(beta)42 lowering agents
12/19/2007EP1131449B1 Method for identifying inhibitors of ipc synthase
12/19/2007EP1115693B9 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY
12/19/2007EP1091757B1 Alpha emitting constructs and uses thereof
12/19/2007EP1005341B1 Il-8 receptor antagonists
12/19/2007EP0954578B1 Glycoprotein hormone (tsh) superagonists
12/19/2007EP0912091B1 Use of gaba uptake inhibitors as anti-tussive agents
12/19/2007CN101090724A Heterocyclic derivatives and their use as therapeutic agents
12/19/2007CN101090721A Selective serotonin receptor inverse agonists as therapeutics for disease
12/19/2007CN101090715A Dendritic cell infiltrativity activating composition and immune activator
1 ... 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 ... 1564